{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T22:53:46Z","timestamp":1771023226755,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40487-025-00389-5","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:40:19Z","timestamp":1761129619000},"page":"881-893","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patient and Physician Perspectives on Multiple Myeloma Data Presented at ASCO and EHA 2025: A Podcast"],"prefix":"10.1007","volume":"13","author":[{"given":"Jenny","family":"Ahlstrom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-2469","authenticated-orcid":false,"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"389_CR1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7502","volume-title":"Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial)","author":"F Gay","year":"2025","unstructured":"Gay F, Roeloffzen W, Dimopoulos MA, Rosi\u00f1ol L, van der Klift M, Oriol A, et al. Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial). Chicago: American Society of Clinical Oncology; 2025."},{"key":"389_CR2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7501","author":"P Moreau","year":"2025","unstructured":"Moreau P, Sonneveld P, Einsele H, Quach H, Ho PJ, Beksac M, et al. Subcutaneous daratumumab (dara)+bortezomib\/lenalidomide\/dexamethasone (VRd) with dara+lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.7501.","journal-title":"J Clin Oncol"},{"key":"389_CR3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7500","author":"A Perrot","year":"2025","unstructured":"Perrot A, Hulin C, Lambert J, Karlin L, Arnulf B, Rey P, et al. MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: primary endpoints of the phase 3 MIDAS trial. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.7500.","journal-title":"J Clin Oncol"},{"key":"389_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1182\/blood-2024-206003","volume":"144","author":"MS Raab","year":"2024","unstructured":"Raab MS, Weinhold N, Kort\u00fcm KM, Kr\u00f6nke J, Podola L, Bertsch U, et al. Phase 2 study of teclistamab-based induction regimens in patients with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) trial. Blood. 2024;144:493.","journal-title":"Blood"},{"key":"389_CR5","volume-title":"Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: initial results from MagnetisMM-6 part 1","author":"H Quach","year":"2025","unstructured":"Quach H, Pour L, Grosicki S, Sia H, Minarik J, Byun JM, et al. Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: initial results from MagnetisMM-6 part 1. Chicago: American Society of Clinical Oncology; 2025."},{"key":"389_CR6","volume-title":"First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Initial phase 1 results","author":"NW Van de Donk","year":"2025","unstructured":"Van de Donk NW, Vega G, Perrot A, Anguille S, Oriol A, Minnema M, et al. First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Initial phase 1 results. Chicago: American Society of Clinical Oncology; 2025."},{"key":"389_CR7","volume-title":"Phase 1, first-in-human study of ISB 2001: A BCMA\u00d7CD38\u00d7CD3-targeting trispecific antibody for patients with relapsed\/refractory multiple myeloma (RRMM)\u2014Dose escalation (DE) results","author":"EI Lichtman","year":"2025","unstructured":"Lichtman EI, Khot A, Augustson B, Levitz D, Sia H, Wong Doo N, et al. Phase 1, first-in-human study of ISB 2001: A BCMA\u00d7CD38\u00d7CD3-targeting trispecific antibody for patients with relapsed\/refractory multiple myeloma (RRMM)\u2014Dose escalation (DE) results. Chicago: American Society of Clinical Oncology; 2025."},{"key":"389_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7507","author":"PM Voorhees","year":"2025","unstructured":"Voorhees PM, Martin TG, Lin Y, Cohen AD, Raje NS, Htut M, et al. Long-term (\u22655 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.7507.","journal-title":"J Clin Oncol"},{"key":"389_CR9","volume-title":"Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed\/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses","author":"S Sidana","year":"2025","unstructured":"Sidana S, Martinez-Lopez J, Khan AM, Oriol A, Spencer A, Dhakal B, et al. Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed\/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses. Chicago: American Society of Clinical Oncology; 2025."},{"key":"389_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7511","volume-title":"Heterogeneity in the expression of GPRC5D between patients with multiple myeloma","author":"H Parmar","year":"2025","unstructured":"Parmar H, Albitar M, Agersborg S, Charifa A, Phull P, Biran N, et al. Heterogeneity in the expression of GPRC5D between patients with multiple myeloma. Chicago: American Society of Clinical Oncology; 2025."},{"issue":"4","key":"389_CR11","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","volume":"31","author":"SZ Usmani","year":"2025","unstructured":"Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med. 2025;31(4):1195\u2013202.","journal-title":"Nat Med"},{"issue":"17","key":"389_CR12","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, Dimopoulos M-A, Leleu XP, Beksac M, Pour L, H\u00e1jek R, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(17):1597\u2013609.","journal-title":"N Engl J Med"},{"issue":"2","key":"389_CR13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2406536","volume":"392","author":"YC Cohen","year":"2025","unstructured":"Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min C-K, et al. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2025;392(2):138\u201349.","journal-title":"N Engl J Med"},{"key":"389_CR14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7018","author":"H Mahadevia","year":"2025","unstructured":"Mahadevia H, Modi K, Sharma P, Peshin S, Shah RN, Modi S, et al. Incidence of infections, cardiac events, neurological toxicity and cytokine response syndrome (CRS) in patients treated with chimeric antigen receptor (CAR) T cell therapy: a 3-year nationwide analysis. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.7018.","journal-title":"J Clin Oncol"},{"issue":"S16","key":"389_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.12040","volume":"43","author":"R Hattin","year":"2025","unstructured":"Hattin R, Aboaid H, Jones DT, Hussain A, Schauer S, Schl T, et al. Incidence of ocular toxicities in patients with relapsed\/refractory multiple myeloma treated with belantamab mafodotin: a systematic review and meta-analysis of phase 3 randomized controlled trials. J Clin Oncol. 2025;43(S16):12040.","journal-title":"J Clin Oncol"},{"key":"389_CR16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7025","volume-title":"Social vulnerability by neighborhood of association correlates with CAR T referrals","author":"CE Anderson","year":"2025","unstructured":"Anderson CE, Scobie MR, Baidya RN, McSkimming D, Rodgers TD, Friedman DR, et al. Social vulnerability by neighborhood of association correlates with CAR T referrals. Chicago: American Society of Clinical Oncology; 2025."},{"key":"389_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7547","volume-title":"Leveraging AI for validating the association between minimal residual disease (MRD) and survival outcomes in multiple myeloma","author":"Z Ren","year":"2025","unstructured":"Ren Z, Zhao Z, Shi Q, Cowan A, Ma W, Xie E. Leveraging AI for validating the association between minimal residual disease (MRD) and survival outcomes in multiple myeloma. Chicago: American Society of Clinical Oncology; 2025."},{"key":"389_CR18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7534","volume-title":"Immune profiling to identify a functionally high-risk smoldering multiple myeloma patient population","author":"R Firestone","year":"2025","unstructured":"Firestone R, Simhal AK, Akhlaghi T, Oh JH, Maclachlan K, Garces J-J, et al. Immune profiling to identify a functionally high-risk smoldering multiple myeloma patient population. Chicago: American Society of Clinical Oncology; 2025."}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00389-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00389-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00389-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:16:13Z","timestamp":1764087373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00389-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["389"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00389-5","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jenny Ahlstrom\n                      : Advisory boards: Bristol Myers Squibb, Johnson & Johnson, Pfizer, Regeneron, Sanofi, and Takeda Oncology;\n                      Luciano J. Costa\n                      : Honoraria: Amgen, Bristol Myers Squibb, AbbVie, Pfizer, Johnson & Johnson, Adaptive Biotechnologies, Sanofi, Genentech\/Roche; Research Funding: Amgen, Bristol Myers Squibb, Johnson & Johnson, AbbVie, Caribou, Gracell, Genentech\/Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This podcast article is based on data presented at the ASCO and EHA 2025 Congresses and it does not contain any new studies with human participants or animals performed by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}